Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
- NCT03976362
- MK-7339-008 KEYLYNK-008 2018-004721-88 7339-008
Trial sponsor
Merck
Scientific Title
A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)